Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

A qualitative study of strategies to improve occupational well‐being in physical medicine and rehabilitation physicians
Amano, Alexis , Trockel, Mickey , Menon, Nikitha K. , Sliwa, James A. , Kinney, Carolyn L. , Knowlton, Tiffany, Stautzenbach, Thomas E., Shanafelt, Tait D. , Sliwa, James , Kinney, Carolyn , Verduzco-Gutierrez, Monica , Shanafelt, Tait D , Makowski, Maryam S , Wang, Hanhan , Weinstein, Stuart L. , Paganoni, Sabrina , Verduzco‐Gutierrez, Monica , Kennedy, David J.

Mayo Clinic

PM&R | June 5, 2024 | Volume: 16 | Issue: 7 | Pages: 687-699

10.1002/pmrj.13189 | PMID 38837667 Get It

Abstract Background Physiatry is a specialty with high rates of burnout. Although organizational strategies to combat burnout are key, it is also important to understand strategies that individual physiatrists can use to address burnout. Objective To identify changes that resulted in improvement of occupational well‐being of physiatrists over a 6‐ to 9‐month period. Design We employed two quantitative surveys spaced 6 to 9 months apart to identify physiatrists who experienced meaningful improvement in occupational burnout and/or professional fulfillment between the two survey timepoints. These physiatrists were subsequently recruited to participate in a qualitative study using semi‐structured interviews to identify changes that respondents felt contributed to improvements in burnout and professional fulfillment. Setting Online surveys and interviews. Participants Physiatrists in the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Membership Masterfile. Main Outcome Measure Burnout and professional fulfillment were assessed using the Stanford Professional Fulfillment Index. Results One hundred twelve physiatrists responded to the baseline and follow‐up surveys. Of these, 35 were eligible for interviews based on improvements in the Stanford Professional Fulfillment Index, and 23 (64%) agreed to participate. Themes from the qualitative interviews highlighted the importance of personal lifestyle choices, approaches to improve professional satisfaction, and strategies to foster work‐life harmony. Personal lifestyle strategies included investing in wellness and mental health. Efforts to improve professional satisfaction included decreasing work intensity, prioritizing meaningful aspects of work, and building relationships with colleagues. Fostering work‐life harmony also included making trade‐offs in both domains, setting boundaries at work, setting expectations at home, and overcoming personal challenges. Conclusion Our findings illustrate that, in addition to organizational strategies demonstrated to be effective, there are actions that individual physiatrists can take to recover from burnout and foster professional fulfillment.
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).
Burguera, Adolfo de la Fuente, Regales, Lucía, Zhao, Wanying, Ferrari, Dora, Fowles, M, Lane, Maureen, Wang, Catherine, Roemeling, Reinhard W. Von, D’Angelo, Christopher R. , Nowakowski, Grzegorz S. , Grommes, Christian , Tun, Han W. , Dąbrowska‐Iwanicka, Anna , Fowles, Meaghan, Lane, Maureen E., Taszner, Michał

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 2087-2087

10.1200/jco.2024.42.16_suppl.2087 Get It

2087 Background: PCNSL is a rare and aggressive form of NHL in the central nervous system or vitreoretinal space. Despite high initial rates of responses to HD-MTX-based induction chemotherapies, most patients relapse in two years. R/R PCNSL is associated with poor prognosis, representing a clear unmet medical need, as there are no currently approved treatments for this disease. IRAK4 kinase activity is required for TLR and IL-1R signaling in a variety of myeloid and lymphoid cell types, including PCNSL. Recruitment of IRAK4 to these receptors and subsequent activation is facilitated by the MyD88 adaptor protein, which is mutated in ~70% of PCNSL. This leads to constitutive activation of the NF-κB signaling pathway, increased inflammation, and tumor growth. Emavusertib is a novel and potent oral inhibitor of IRAK4 and FLT3, which has demonstrated the ability to cross the blood-brain barrier in PCNSL xenografts. In preclinical studies, the combination of emavusertib with ibrutinib overcomes resistance to BTK inhibitors. This combination has an acceptable safety profile across a broad population of R/R NHL patients, including PCNSL. Here we present updated safety and efficacy data for emavusertib in combination with ibrutinib in patients with R/R PCNSL. Methods: The safety, clinical activity, and potential biomarkers of emavusertib in R/R PCNSL are being investigated in the ongoing open-label, Phase 1/2 TakeAim Lymphoma trial (NCT03328078). The eligible patients with R/R PCNSL received emavusertib (100-300 mg BID) in combination with ibrutinib (560 mg QD) in a 21-day cycle until tumor progression or unacceptable toxicity. Results: Here, we present updated data from R/R PCNSL patients with prior ibrutinib exposure who were treated with emavusertib in combination with ibrutinib. The median number of prior lines of anti-cancer therapies was 3 (range: 2-5), all patients were R/R to both frontline therapy and subsequent ibrutinib regimens. Prior responses to ibrutinib based regimens included only 1 CR. Here, we report a higher CR rate when these patients are subsequently treated with emavusertib in combination with ibrutinib.Results revealed no dose-limiting toxicities. Conclusions: Emavusertib in combination with ibrutinib was well tolerated with an acceptable safety profile and promising efficacy in R/R PCNSL patients with previous exposure to ibrutinib (BTKi). Enrollment in this trial is ongoing (NCT03328078). Clinical trial information: NCT03328078 .
Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
Gondi, Vinai , Ilić, Rosanda , Muanza, Thierry , Krpan, Ana Mišir , Ramakrishna, Naren , Fiveash, John B. , Métellus, Philippe , Wang, Chiachien Jake, Feuvret, L. , Csőszi, Tibor , Brown, Paul D. , Zhu, Zhengfei, Yu, Jinming , Mehta, Minesh P. , Ahluwalia, Manmeet S. , Roberge, David , Sio, Terence T. , Trifiletti, Daniel M. , Freyschlag, Christian Franz , Zhu, Zhengfei , Harat, Maciej

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 2008-2008

10.1200/jco.2024.42.16_suppl.2008 Get It

2008 Background: For non-small cell lung cancer (NSCLC) with brain metastases (BM) stereotactic radiosurgery (SRS) is the current preferred therapy. Due to frequent intracranial failures, there is a high unmet need for salvage therapies. Whole brain radiotherapy (WBRT) reduces intracranial failure but used less frequently due to cognitive consequences. Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division and have shown improved survival and safety in patients with glioblastoma and metastatic NSCLC. Phase 3 METIS trial [NCT02831959] aimed to evaluate the efficacy and safety of TTFields therapy in NSCLC patients with BM treated with SRS, specifically in terms of lengthening time to intracranial progression without cognitive decline. Methods: Mutation negative (M-) NSCLC patients with 1–10 BM were randomized 1:1 to receive stereotactic radiosurgery (SRS) followed by Tumor Treating Fields (TTFields; 150 kHz) therapy with best supportive care (BSC) or SRS followed by BSC. Patients with Karnofsky Performance Status (KPS) ≥70, newly diagnosed with one inoperable or 2–10 supra-/infratentorial brain metastases suitable for SRS and receiving optimal extracranial disease therapy were included. Exclusions were prior WBRT and single operable or recurrent brain metastases. Primary endpoint was time to first intracranial progression (RANO-BM) based on cumulative risk. Patients were followed every two months until second intracranial progression. Cognition and patient quality of life (QoL) were evaluated. Results: Between July 2016 and September 2022, 298 patients were randomized. Baseline characteristics were balanced: median age was 63.5 (range 37-84) years, 37.6% females, majority of patients had a KPS ≥ 80, median time from initial NSCLC diagnosis was 1.8 months (range: 0.2-55.7), 77% had adenocarcinoma. Median treatment duration of TTFields was 16 weeks, with a median usage time of 67%. Primary endpoint, time to intracranial progression from SRS, was significantly prolonged with SRS followed by TTFields therapy with BSC vs. BSC alone arm (median of 21.9 vs. 11.3 months); HR=0.67 [0.48-0.93], p=0.02. TTFields-related AEs were mainly dermatological, and Grade ≤2. TTFields therapy also improved deterioration-free survival of global health status, physical functioning, and fatigue according to QoL, and did not negatively impact cognition. Conclusion: METIS study met its primary endpoint, demonstrating that TTFields therapy following SRS in mutation negative NSCLC patients with BM, significantly prolongs time to intracranial progression and could postpone WBRT, without QoL and cognition decline. Clinical trial information: NCT02831959 .
Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry
Hua, Wei , Brown, Hannah Marie , Fang, Xinqi , Shahi, Mahdiyeh , Chen, Rong , Jiao, Bin , Wang, Nan , Xu, Hao , Wang, Xiaowen , Zhang, Jinsen , Wang, Qijun , Ye, Dan , Chaichana, Kaisorn L. , Mao, Ying , Quiñones‐Hinojosa, Alfredo , Shahi, Mahdiyeh , Garcia, Diogo Moniz-, Chaichana, Kaisorn, Cooks, R Graham , Quinones-Hinojosa, Alfredo , Zhang, Wenpeng , Wu, Junhan , Zhang, Haoyue , Jiao, Bin, Fu, Minjie , Zhang, Xin , Zhu, Wei Ping , Moniz‐Garcia, Diogo , Cooks, R. Graham , Ouyang, Zheng

Mayo Clinic

Proceedings of the National Academy of Sciences | June 2, 2024 | Volume: 121 | Issue: 23 | Pages: No page available

10.1073/pnas.2318843121 | PMID 38805277 Get It

The development and performance of two mass spectrometry (MS) workflows for the intraoperative diagnosis of isocitrate dehydrogenase (IDH) mutations in glioma is implemented by independent teams at Mayo Clinic, Jacksonville, and Huashan Hospital, Shanghai. The infiltrative nature of gliomas makes rapid diagnosis necessary to guide the extent of surgical resection of central nervous system (CNS) tumors. The combination of tissue biopsy and MS analysis used here satisfies this requirement. The key feature of both described methods is the use of tandem MS to measure the oncometabolite 2-hydroxyglutarate (2HG) relative to endogenous glutamate (Glu) to characterize the presence of mutant tumor. The experiments i) provide IDH mutation status for individual patients and ii) demonstrate a strong correlation of 2HG signals with tumor infiltration. The measured ratio of 2HG to Glu correlates with IDH-mutant (IDH-mut) glioma ( P < 0.0001) in the tumor core data of both teams. Despite using different ionization methods and different mass spectrometers, comparable performance in determining IDH mutations from core tumor biopsies was achieved with sensitivities, specificities, and accuracies all at 100%. None of the 31 patients at Mayo Clinic or the 74 patients at Huashan Hospital were misclassified when analyzing tumor core biopsies. Robustness of the methodology was evaluated by postoperative re-examination of samples. Both teams noted the presence of high concentrations of 2HG at surgical margins, supporting future use of intraoperative MS to monitor for clean surgical margins. The power of MS diagnostics is shown in resolving contradictory clinical features, e.g., in distinguishing gliosis from IDH-mut glioma.
Impact of educational background on preoperative disease severity and postoperative outcomes among patients with lumbar spondylolisthesis: a Quality Outcomes Database study
Chan, Andrew K. , Bisson, Erica F. , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Gottfried, Oren N., Tumialán, Luis M. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Mitha, Rida , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Haid, Regis W., Chou, Dean , Bydon, Mohamad , Mummaneni, Praveen V. , Agarwal, Nitin , Ibrahim, Sufyan , Michalopoulos, Giorgos D. , Park, Paul , Guan, Jian

Mayo Clinic

Journal of Neurosurgery: Spine | June 1, 2024 | Volume: 41 | Issue: 3 | Pages: 341-352

10.3171/2024.3.spine231024 | PMID 38820603 Get It

OBJECTIVE Deficiency in patient education has been correlated with increased disease-related morbidity and decreased access to care. However, the associations between educational level, preoperative disease severity, and postoperative outcomes in patients with lumbar spondylolisthesis have yet to be explored. METHODS The spondylolisthesis dataset of the Quality Outcomes Database (QOD)—a cohort with prospectively collected data by the SpineCORe study team of the 12 highest enrolling sites with an 81% follow-up at 5 years —was utilized and stratified for educational level. Patients were classified into three categories (high school or less, graduate, or postgraduate). Patient-reported outcome measures (PROMs) documented at baseline and follow-up included Oswestry Disability Index (ODI) score, EQ-5D in quality-adjusted life years, and numeric rating scale (NRS) scores for back and leg pain. Disease severity was measured with PROMs. Postoperatively, patients also completed the North American Spine Society assessment to measure their satisfaction with surgery. Multivariable regression analysis was used to compare education level with disease severity and postoperative outcomes. RESULTS A total of 608 patients underwent analysis, with 260 individuals (42.8%) at an educational level of high school or less. On univariate analysis, baseline disease severity was worse among patients with lower levels of education. On multivariable regression analysis, patients with postgraduate level of education had significantly lower ODI scores (β = −3.75, 95% CI −7.31 to −0.2, p = 0.039) compared to graduates, while the other PROMs were not associated with significant differences at baseline. Five years postoperatively, patients from various educational backgrounds exhibited similar rates of minimal clinically important differences in PROMs. Nevertheless, patients with the lowest educational level had higher ODI scores (27.1, p < 0.01), lower EQ-5D scores (0.701, p < 0.01), and higher NRS leg pain (3.0, p < 0.01) and back pain (4.0, p < 0.01) scores compared to those with graduate or postgraduate levels of education. The odds for postoperative satisfaction were also comparable between cohorts at 5 years (reference, graduate level; high school or less, OR 0.87, 95% CI 0.46–1.64, p = 0.659; postgraduate, OR 1.6, 95% CI 0.7–3.65, p = 0.262). CONCLUSIONS Lower patient education level was associated with a greater baseline disease severity in patients with lumbar spondylolisthesis. Surgery demonstrated similar benefits irrespective of educational background; however, individuals with lower educational level reported lower outcomes overall. This emphasizes the need for enhanced health literacy to mitigate disparities for reported outcomes.
BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression
Rivero, Seleste L, Shen, Keyi , Li, Zixuan , Niu, Tianhua , Rowan, Brian G., Jazwinski, S. Michal, Steele, Chad , Wang, Alun R. , Zhang, Qiuyang , Zhang, Qiuyang , Liu, Sen , Zhang, Bing , Abdel‐Mageed, Asim B. , Sartor, Oliver

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 1, 2024 | Volume: 116 | Issue: 10 | Pages: 1598-1611

10.1093/jnci/djae120 | PMID 38833676 Get It

Abstract Background The role of Th17 cells in prostate cancer is not fully understood. The transcription factor BATF controls the differentiation of Th17 cells. Mice deficient in Batf do not produce Th17 cells. Methods In this study, we aimed to characterize the role of Batf-dependent Th17 cells in prostate cancer by crossbreeding Batf knockout mice with mice conditionally mutant for Pten. Results We found that Batf knockout mice had changes in the morphology of prostate epithelial cells compared with normal mice, and Batf knockout mice deficient in Pten (called Batf-) had smaller prostate size and developed fewer invasive prostate adenocarcinomas than Pten-deficient mice with Batf expression (called Batf+). The prostate tumors in Batf- mice showed reduced proliferation, increased apoptosis, decreased angiogenesis and inflammatory cell infiltration, and activation of nuclear factor–κB signaling. Moreover, Batf- mice showed significantly reduced interleukin 23 (IL-23)-IL-23R signaling. In the prostate stroma of Batf- mice, IL-23R–positive cells were decreased considerably compared with Batf+ mice. Splenocytes and prostate tissues from Batf- mice cultured under Th17 differentiation conditions expressed reduced IL-23/IL-23R than cultured cells from Batf+ mice. Anti–IL-23p19 antibody treatment of Pten-deficient mice reduced prostate tumors and angiogenesis compared with control immunoglobulin G–treated mice. In human prostate tumors, BATF messenger RNA level was positively correlated with IL-23A and IL-23R but not RORC. Conclusion Our novel findings underscore the crucial role of IL-23-IL-23R signaling in mediating the function of Batf-dependent Th17 cells, thereby promoting prostate cancer initiation and progression. This finding highlights the BATF–IL-23R axis as a promising target for the development of innovative strategies for prostate cancer prevention and treatment.
Extensive scintigraphic gastric motor function testing with concurrent symptom recording predicts prospectively measured daily dyspeptic symptoms
Wang, Xiao Jing , OʼConnor, Michael , Peck, Taylor, Prichard, David O. , Johnston, Geoffrey, Prichard, David , Wang, Xiao Jing , Johnston, Geoffrey

Mayo Clinic

Neurogastroenterology & Motility | May 31, 2024 | Volume: 36 | Issue: 8 | Pages: No page available

10.1111/nmo.14819 | PMID 38816956 Get It

AbstractBackgroundAbsent “organic” disease, dyspeptic symptoms may arise from abnormal gastric sensation, accommodation, motility or emptying (GE). Extensive gastric sensorimotor evaluation is rarely undertaken because testing is prolonged, invasive, poorly tolerated or unavailable.AimsTo investigate whether gastric antral motor function, evaluated with scintigraphy, predicts GE. To explore whether motor testing with symptom recording predicts day‐to‐day symptoms in patients with dyspepsia.MethodsGE was determined using a scintigraphic solid‐meal protocol (296 kcal, 35% fat). Antral motility was estimated from 10 min of scintigraphic time‐activity curves acquired 40 min after meal consumption. An antral motility index (MI) was derived from contraction amplitude and frequency. Intra‐gastric distribution of the meal on scintograms at 1 h (IGD1) was determined. Meal‐induced symptoms were evaluated by questionnaire. Patients completed the Gastroparesis Cardinal Symptom Index Daily Diary (GCSI‐DD) for 14 days.ResultsTwelve healthy participants and 23 prospectively recruited patients completed the study. Nine patients had delayed, and 2 had rapid, GE. In univariate analysis MI explained 42% of GE half‐time. In multivariate analysis MI and GE half‐time explained 25% of the variance in meal‐induced symptoms. While scintigraphic evaluation of gastric motor function with symptom recording explained 80% of the variance in the GCSI‐DD, meal‐induced symptoms were the only significant predictor. However, among patients with delayed GE, MI, GE half‐time, IGD1, and meal‐induced symptoms all significantly predicted GCSI‐DD.ConclusionsAntral motility predicts GE. In exploratory analyses, only meal‐induced symptoms predicted daily symptoms among patients with dyspepsia. However, motor function also predicted symptoms in patients with delayed GE.
Symptom cluster profiles predict all-cause mortality among older adults with heart failure
Chyun, Deborah , Wang, Zequan , Walsh, Stephen J. , Jeon, Sangchoon , Conley, Samantha , Redeker, Nancy S.

Mayo Clinic

No container title available | May 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4414292/v1 Get It

Abstract Background Heart failure (HF) has a high mortality risk in older adults. Individual symptoms as predictors of mortality in HF patients; however, symptoms often manifest in clusters, which may be more predictive of future risks than isolated symptoms. However, research on symptom clusters in older adults who have HF is limited. To explore the extent to which symptom cluster profiles predict all-cause mortality among older adults with HF, while adjusting for demographic and clinical factors. Methods A secondary study was conducted using the data from the Health and Retirement Study. We measured six symptoms (fatigue, shortness of breath, pain, swelling, depressive symptoms, and dizziness), and used latent class analysis to identify baseline symptom cluster profile. We performed survival analysis for time to death with Kaplan Meier survival analyses and Cox Proportional Hazard models. Results The sample included 684 participants (mean age = 74.9 (SD = 10.0) years) who demonstrated three symptom cluster profiles (high-burden, low-burden, and cardiopulmonary-depressive). The estimated median time-to-death was 71 (95% CI= [64, 79]) months. Participants in the high symptom burden and respiratory-depressive distress profiles had adjusted hazard ratios of 1.48 (95% CI = 1.15, 1.94) and 1.44 (95% CI = 1.14, 1.80) for time to death compared to those in the low burden profile. Conclusion Symptom profiles can assist in identifying older adults with HF who are at risk for earlier mortality. Further research is needed to determine whether alleviating these symptom clusters decreases the risk of mortality.
FACTORS ASSOCIATED WITH DELAYED DIAGNOSIS IN PATIENTS WITH PRIMARY VITREORETINAL LYMPHOMA
Wang, Kenny Y. , Xu, Timothy T. , Mogil, Rachel S., Song, Allisa J. , White, Launia J. , Hodge, David O. , Dalvin, Lauren A. , Dalvin, Lauren A

Mayo Clinic

Retina | May 29, 2024 | Volume: 44 | Issue: 10 | Pages: 1800-1806

10.1097/iae.0000000000004169 | PMID 39287543 Get It

Purpose: To identify demographic and clinical factors associated with delayed diagnosis in patients with primary vitreoretinal lymphoma (VRL). Methods: Retrospective, tertiary referral center-based cohort study of all patients at Mayo Clinic in Rochester, Minnesota, with a biopsy-proven diagnosis of VRL from January 1, 2000, to October 31, 2022. Results: There were 87 patients included during the 22-year study period with 73 patients (83.9%) diagnosed with VRL upon initial evaluation at the tertiary center, with the other 14 patients (16.1%) diagnosed later. The median referral time was 4.8 months (range: 0–113 months). Patients who received an initial diagnosis of inflammatory uveitis or another incorrect diagnosis elsewhere were referred slower than those initially diagnosed with VRL (P = 0.04). The most common incorrect initial diagnosis from an outside institution was inflammatory uveitis (n = 35, 40.2%). When patients were split into four groups based on referral time, prior use of corticosteroids was associated with a significant delay in referral (P = 0.03). Conclusion: Diagnosing VRL continues to be challenging, as months-long delays from initial evaluation to expert referral center evaluation are common. Prior use of corticosteroids was associated with delay in diagnosis and referral time, underscoring the need to increase awareness regarding differences between VRL and uveitis.
Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer
Drew, David A. , Kim, Andre E. , Lin, Yi , Morrison, John L. , Lewinger, Juan Pablo , Fu, Yubo, Zemlianskaia, Natalia , Díez‐Obrero, Virginia , Baurley, James W. , Wu, Anna H. , Prentice, Ross L. , Harlid, Sophia , Barry, Elizabeth L. , Berndt, Sonja I. , Bouras, Emmanouil , Burnett‐Hartman, Andrea N. , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Newton, Christina C. , Obón‐Santacana, Mireia , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Peters, Ulrike , Gauderman, W. James , Morrison, John L , Lewinger, Juan Pablo , Wang, Jun , Zemlianskaia, Natalia , Bien, Stephanie A , Dimou, Niki , Buchanan, Daniel D , Potter, John D , Prentice, Ross L , Harlid, Sophia , Arndt, Volker , Bouras, Emmanouil , Carreras-Torres, Robert , Casey, Graham , Devall, Matthew A M , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kundaje, Anshul , Li, Li , Lynch, Brigid M , Nassir, Rami , Newton, Christina C , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Pardamean, Bens , Pellatt, Andrew J , Peoples, Anita R , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Su, Yu-Ru , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , Um, Caroline Y , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Hsu, Li , Moreno, Victor , Peters, Ulrike , Chan, Andrew T , Gauderman, W James , Drew, David A , Obón-Santacana, Mireia , Papadimitriou, Nikos , Diez-Obrero, Virginia , Qu, Conghui , Kawaguchi, Eric , Bien, Stephanie A. , Dimou, Niki , Albanes, Demetrius , Buchanan, Daniel D. , Potter, John D. , Arndt, Volker , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T. , Carreras‐Torres, Robert , Conti, David V. , Gunter, Marc J. , Hidaka, Akihisa , Hoffmeister, Michael , Jenkins, Mark A. , Marchand, Loı̈c Le , Murphy, Neil , Nassir, Rami , Newcomb, Polly A. , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Stern, Mariana Carla , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Um, Caroline Y. , White, Emily E. , Moreno, Vı́ctor , Chan, Andrew T.

Mayo Clinic

Science Advances | May 29, 2024 | Volume: 10 | Issue: 22 | Pages: No page available

10.1126/sciadv.adk3121 | PMID 38809988 Get It

Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.